Accelerate Diagnostics (FRA:1A80) Net Change in Cash : €-13.75 Mil (TTM As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Accelerate Diagnostics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Accelerate Diagnostics's Net Change in Cash for the three months ended in Mar. 2024 was €2.27 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was €-13.75 Mil.

Accelerate Diagnostics Net Change in Cash Historical Data

The historical data trend for Accelerate Diagnostics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Net Change in Cash Chart

Accelerate Diagnostics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

-4.72

-20.74

3.64

-4.71

-20.88

Accelerate Diagnostics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															-5.14	-0.12	-8.55	-7.36	2.27

Accelerate Diagnostics Net Change in Cash Calculation

Accelerate Diagnostics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-36.86	+	7.941	+	8.27	+	-0.229
	=	-20.88

Accelerate Diagnostics's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -7.776 + -0.472 + 10.524 + -0.006

= 2.27

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accelerate Diagnostics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Accelerate Diagnostics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerate Diagnostics (FRA:1A80) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (FRA:1A80) » Definitions » Net Change in Cash

Comparable Companies

SSKN SNWV TLIS PAVM RMSL BSGM PETV BTCY BMRA NMTC ABT SYK BSX MDT XTER:SHL EW SZSE:300760 DXCM ZBH ALGN

Traded in Other Exchanges

AXDX:USA AXDX:Mexico

Address

3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714

Website

https://www.acceleratediagnostics.com

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Accelerate Diagnostics (FRA:1A80) Headlines

No Headlines